Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
mg decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
5 step » _ step (Expand Search), a step (Expand Search), 2 step (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
mg decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
5 step » _ step (Expand Search), a step (Expand Search), 2 step (Expand Search)
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif
Published 2021“…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
-
50
-
51
Uganda 2023 NCD risk factor STEPS survey data.
Published 2025“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
-
52
Uganda 2014 NCD risk factor STEPS survey data.
Published 2025“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
-
53
-
54
-
55
-
56
DataSheet_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.docx
Published 2021“…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
-
57
Discovery of Novel Substituted <i>N</i>‑(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors
Published 2020“…Notably, among these derivatives, compound <b>15</b> showed improved anti-HAdV activity (IC<sub>50</sub> = 0.27 μM), significantly decreased cytotoxicity (CC<sub>50</sub> = 156.8 μM), and low <i>in vivo</i> toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosamide, supporting its further <i>in vivo</i> efficacy studies for the treatment of HAdV infections.…”
-
58
-
59
-
60